Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Symbicort add-on to Tiotropium in severe COPD
NCT00496470Phase 4Completed
- Sponsor
- AstraZeneca
- Start
- May 2007
- Primary completion
- Jun 2008
- Modality
- Orthosteric Ligands
- Countries
- 9
01
Overview
Phase 4, randomised, double-blind trial of budesonide in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by AstraZeneca. Primary endpoint: Forced Expiratory Volume in 1 Second (FEV1) Pre-dose at 12 weeks. Started May 2007; status: completed.
02
Drugs
budesonide
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT00496470.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00496470.